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Abstract
The CA 19-9 assay detects a carbohydrate antigen on multiple protein carriers, some of which may be preferential carriers of
the antigen in cancer. We tested the hypothesis that the measurement of the CA 19-9 antigen on individual proteins could
improve performance over the standard CA 19-9 assay. We used antibody arrays to measure the levels of the CA 19-9
antigen on multiple proteins in serum or plasma samples from patients with pancreatic adenocarcinoma or pancreatitis.
Sample sets from three different institutions were examined, comprising 531 individual samples. The measurement of the
CA 19-9 antigen on any individual protein did not improve upon the performance of the standard CA 19-9 assay (82%
sensitivity at 75% specificity for early-stage cancer), owing to diversity among patients in their CA 19-9 protein carriers.
However, a subset of cancer patients with no elevation in the standard CA 19-9 assay showed elevations of the CA 19-9
antigen specifically on the proteins MUC5AC or MUC16 in all sample sets. By combining measurements of the standard CA
19-9 assay with detection of CA 19-9 on MUC5AC and MUC16, the sensitivity of cancer detection was improved relative to
CA 19-9 alone in each sample set, achieving 67–80% sensitivity at 98% specificity. This finding demonstrates the value of
measuring glycans on specific proteins for improving biomarker performance. Diagnostic tests with improved sensitivity for
detecting pancreatic cancer could have important applications for improving the treatment and management of patients
suffering from this disease.
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Introduction
Several factors contribute to the extremely poor prognosis
associated with pancreatic cancer, including the resistance of the
disease to available therapeutic options, its tendency to metastasize
at small primary tumor sizes, and its induction of cachexia [1].
The lack of effective tools for accurately detecting and diagnosing
the disease at early stages further contributes to the problems in
treating the disease. Because of the lack of early detection
methods, most pancreatic cancers are detected at an advanced
stage. Furthermore, because established disease can be difficult to
diagnose due to clinical similarities with certain benign diseases
such as chronic pancreatitis [2], some patients may receive sub-
optimal treatment. Current diagnostic modalities include non-
invasive imaging, endoscopic ultrasound, and cytology based on
fine-needle aspiration [3]. These methods are useful for identifying
pancreatic abnormalities and rendering an accurate diagnosis in
many cases, but they come with high cost, significant expertise
required for interpretation, and inherent uncertainty. Molecular
markers could provide a useful complement to imaging and
cytology methods, since they have the potential to provide
objective information in an inexpensive, routine assay. Therefore,
identifying and developing molecular markers providing useful
diagnostic information for pancreatic cancer is a high priority.
The CA 19-9 serum marker is elevated in the majority of
pancreatic cancer patients but does not achieve the performance
required for either early detection or diagnosis, due to both false
positive and false negative readings [4]. Patients with biliary
obstruction, liver diseases, and pancreatitis may have elevations in
CA 19-9, so its elevation is not exclusively specific for malignancy.
In addition, some patients with cancer do not show elevation [5],
reducing its usefulness for confirming cancer in suspect cases. The
information from CA 19-9 is useful, in coordination with other
clinical factors, for monitoring disease progression in patients
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receiving therapy [6]. Methods to improve detection of the
patients who are low in CA 19-9, or to reduce false detection of
patients with non-malignant elevations in CA 19-9, would be
useful for developing effective pancreatic cancer biomarkers.
The nature of the CA 19-9 antigen suggests a strategy for
potentially improving biomarker performance. The CA 19-9
antigen is a carbohydrate structure called sialyl LewisA (part of the
Lewis family of blood group antigens) with the sequence
Neu5Aca2,3Galb1,3(Fuca1,4)GlcNAc. Sialyl LewisA is synthe-
sized by glycosyltransferases that sequentially link the monosac-
charide precursors onto both N-linked and O-linked glycans. Sialyl
LewisA is not found at a high level in normal tissues, but it is found
in embryonic tissue [7] and overexpressed in certain epithelial
cancers and inflammatory conditions [4]. It is attached to many
different proteins, including mucins, carcinoembryonic antigen
[8,9], and circulating apolipoproteins [10]. In the standard CA 19-
9 clinical assay, a monoclonal antibody captures and detects the
CA 19-9 antigen in a sandwich ELISA format, which measures the
CA 19-9 antigen on many different carrier proteins [9].
It is possible that the carrier proteins of the CA 19-9 antigen are
different between disease states, as suggested earlier [10,11]. If that
is the case, the detection of the CA 19-9 antigen on particular
carrier proteins may yield improved discrimination of the disease
states, in comparison to measurements of total CA 19-9. We
previously demonstrated a method for detecting the level of
particular glycans on individual proteins captured out of biological
solutions [12,13,14]. Antibody arrays capture multiple, different
proteins, and glycan-binding lectins or antibodies detect the glycan
levels on the captured proteins. This method provides sensitive
and reproducible measurements in low sample volumes and is
compatible with high-throughput sample processing [15]. Previous
work using this method showed that the mucins MUC1,
MUC5AC, and MUC16 are major cancer-associated carriers of
the CA 19-9 antigen in the blood [13]. In this work, we tested the
hypothesis that the detection of the CA 19-9 antigen on specific
proteins can yield improved biomarker performance over total CA
19-9 in the detection of cancer. We tested this hypothesis for the
particularly difficult diagnostic problem of differentiating pancre-
atic cancer patients from pancreatitis patients [2], for which CA
19-9 alone does not give sufficient performance to be clinically
useful. We show that clear distinctions exist between patients in the
proteins that carry the CA 19-9 antigen, and that a biomarker
panel based on the detection of the CA 19-9 on specific proteins
accurately identifies a greater percentage of cancer patients than
the conventional CA 19-9 assay.
Results
Profiling the CA 19-9 antigen on specific proteins
We used antibody arrays to measure the level of the CA 19-9
antigen on specific proteins in multiple samples. Serum and
plasma samples were incubated on antibody arrays, and the arrays
were probed with the CA 19-9 antibody (Fig. 1a) to detect either
the total level of its target antigen (detected at the CA 19-9 capture
antibody) or its level on particular proteins (detected at the capture
antibodies against specific proteins) (Fig. 1b). Each antibody was
printed in triplicate, and the locations of the triplicate spots were
randomized to minimize potential positional bias within each
array. The ability to print and process 48 antibody arrays on a
single microscopic slide enabled the efficient evaluation of multiple
clinical samples (Fig. 1a). Dilution curves of pooled serum/plasma
samples generated in our previous study [13] confirmed the
detection of the targeted proteins or glycans in the linear response
range at a two-fold dilution, and the use of negative control
antibodies (mouse mAbs lacking specificity for any human protein)
and negative control arrays (arrays incubated with PBS buffer
instead of serum or plasma) confirmed a lack of non-specific
binding to the capture antibodies by the detection reagents. The
various capture antibodies displayed distinct binding patterns
(Fig. 1c), consistent with the unique specificities of the antibodies.
Figure 1. Detection of total CA19-9 and CA 19-9 on individual
proteins using antibody arrays. a) High-throughput sample
processing and array-based sandwich assays for CA19-9 detection.
Forty-eight identical arrays are printed on one microscopic slide,
segregated by hydrophobic wax boundaries (left). A set of serum or
plasma samples are incubated on the arrays in random order, and the
arrays for the entire sample set are probed with the CA 19-9 detection
antibody (right). b) Molecular detail. Total CA19-9 is measured at the
CA19-9 capture antibody (left), and CA19-9 on specific proteins is
measured at the individual antibodies against those proteins (right). b)
Representative raw image data from each of the sample groups.
Triplicates of each antibody were randomly positioned on the array, as
indicated for selected antibodies.
doi:10.1371/journal.pone.0029180.g001
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In order to determine which antibodies should be used to profile
CA 19-9 levels over many patients, we profiled a pilot set of 12
serum samples (6 from pancreatic cancer patients and 6 from
pancreatitis patients) using arrays containing 58 different antibod-
ies (Fig. S1). The antibodies targeted a variety of serum proteins,
mucins, matrix proteins, adhesion proteins, and cytokines (Table
S1). Antibodies that were likely to capture a protein carrying the
CA 19-9 antigen were identified based on signal relative to
background and standard deviation across the samples. In
addition, those binding potential markers of disease were identified
by statistical comparison between the patient groups. Eight
candidate protein carriers were identified, with four of them
showing differences between the groups, and in follow up
experiments using smaller arrays (16 antibodies, Table S2) and a
larger sample set (20 case and 24 control samples), two protein
carriers were consistently identified: MUC16 and MUC5AC.
MUC1 was significant in the larger scale experiment. This result is
consistent with a previous study that showed increased levels and
altered glycosylation of these proteins in the blood of pancreatic
cancer patients [13].
Based on the above result, subsequent experiments were
performed using arrays targeting CA 19-9 and the mucin proteins
MUC1, MUC5AC, and MUC16 (see Table S3 for information on
the antibodies). Four to five different monoclonal antibodies were
used for each protein, and each antibody was printed in triplicate.
Three independent sample sets, obtained from three different
institutions (Table 1), were processed, and sample set 1 was
processed blinded and in triplicate on different days with distinct
batches of microarrays. The third replicate of sample set 1 was
primarily used for the analysis here due to minor improvements in
the methods used for that replicate.
The first goal of the analysis was to determine whether the
detection of the CA 19-9 antigen on any individual protein
performed as well or better than the standard CA 19-9 assay
(referred to as total CA 19-9). Each of the proteins MUC1,
MUC5AC, and MUC16 showed significantly higher levels in the
cancer patients than in the pancreatitis patients, both for early and
late stage cancers (Fig. 2). (Results from the best-performing
capture antibodies are shown; the other antibodies targeting these
proteins showed similar results but weaker discrimination between
the groups.) The detection of CA 19-9 on MUC16 had
performance statistically equivalent to that of total CA 19-9, with
a detection of early-stage cancer at 82% sensitivity and 77%
specificity, and a detection of late-stage cancer at 90% sensitivity
and 77% specificity. Sample sets 2 and 3 also showed the same
relationships (not shown). (Sample set 3 showed evidence of
systematic bias between the cases and controls, so was used to
confirm relationships between markers but is not presented in the
subsequent analyses.) Therefore, using these proteins, the
detection of CA 19-9 on an individual protein does not exceed
the performance of the standard CA 19-9 assay. However, the
very good discrimination between groups shows that these proteins
are major disease-associated carriers of the CA 19-9 antigen.
Patient diversity in CA 19-9 carrier proteins
We next investigated the relationships between total CA 19-9
and CA 19-9 on individual proteins to determine whether
elevations occur independently from one another. If non-
overlapping patients are elevated in separate markers, the markers
could be used together to yield improved performance. This
potential was supported by the lack of significant correlation
between total CA 19-9 and CA 19-9 on individual proteins or
between the individual proteins (not shown).
The primary images from selected samples provided insights into
the diversity between samples in the carrier proteins that display the
CA 19-9 antigen (Fig. 3). The amount of signal at the various
capture antibodies gives an indication of the proteins where the CA
19-9 antigen is found. In samples with clearly elevated CA 19-9
(above a 75% specificity threshold), most of the mucin proteins
captured here display CA 19-9. Among the samples with total CA
19-9 levels below a 75% specificity threshold, about half show that
at least one of the mucins captured here display the CA 19-9 antigen
(the prominent mucin carriers are indicated). Other samples show
discernable total CA 19-9 but show that these mucins are not
carriers of the antigen, and a smaller subset shows no detectable
total CA 19-9. Similar subgroups were found in Sets 2 and 3 (not
shown), and Western blot analysis confirmed these patterns of CA
19-9 distribution in selected plasma samples (Fig. S2). These
findings support the concepts that mucins are major carriers of the
CA 19-9 antigen even in low total CA 19-9 states; that diversity
exists between people in which mucins carry the antigen; and that
other protein besides the mucins probed here carry the CA 19-9
antigen in some patients.
The possibility of detecting other glycans to complement the CA
19-9 antigen was suggested by the primary images (Fig. 3). The
samples had been run with detection using the Bauhinea Purpurea
lectin (BPL) and Wheat Germ Agglutinin (WGA) as a preliminary
look at other glycans besides the CA 19-9 antigen. One of the cancer
samples that showed negligible signal at any antibody using CA 19-9
detection (sample LC3607) showed clear signal at the MUC5AC
antibody using detection with BPL. This result indicates that the
MUC5AC mucin is present in the sample and that it does not carry
the CA 19-9 antigen, but that it may be detected using another
glycan. Although a preliminary result from a single patient, this
comparison suggests the importance of detecting other glycans
besides the CA19-9 antigen for further performance improvement,
especially in the cancer patients with no CA19-9 present.
Because no single protein is the dominant cancer-specific carrier
of the CA 19-9 antigen, the detection of CA 19-9 on any of these
individual proteins does not out-perform total CA 19-9. However,
for individual patients, the detection of the CA 19-9 antigen on the
predominant cancer-associated carrier for that patient may give
Table 1. Sets of serum and plasma used in the study.
Set # Set provider
Early-stage
cancer (Stage I, II)
Undetermined
stage cancer
Late-stage cancer
(Stage III, IV) Pancreatitis Healthy Total
1 University of Pittsburgh (UP) 54 13 58 51 54
2 Evanston Northwestern
Healthcare (ENH)
60 9 63 36 52 531
3 University of Michigan (UM) 28 15 38
doi:10.1371/journal.pone.0029180.t001
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improved discrimination of benign from malignant disease,
relative to the total CA 19-9 assay. A panel of such markers, in
which each member of the panel detects a subgroup of patients
elevated in a certain carrier protein, could thus yield improved
performance.
Improved accuracy using a panel of CA 19-9 detection on
individual proteins
The above observations led to the investigation of whether CA
19-9 on individual proteins could complement total CA 19-9
measurements for improved biomarker performance. The rela-
tionship between the measurements of total CA 19-9 and CA 19-9
on certain individual proteins showed this possibility (Fig. 4). In
some cases, patients that were low in total CA 19-9 were
distinguishable from pancreatitis patients by their CA19-9 level on
MUC16 or MUC5AC. MUC1 did not show this relationship (not
shown). Thresholds could be set by which several cancer patients
but no pancreatitis patients were elevated in either CA 19-9 on
MUC5AC or CA 19-9 on MUC16 but not in total CA 19-9.
Using a combination rule in which an elevation (above the
threshold determined individually for each marker) in either total
CA 19-9 or CA 19-9 on an individual protein indicated a ‘‘case,’’
Figure 2. Total CA 19-9 levels and CA 19-9 on specific proteins. The fluorescence values for the total CA 19-9 (top), CA19-9 on MUC1 (second
row), CA 19-9 on MUC16 (third row), and CA 19-9 on MUC5AC (fourth row) are shown for each sample group. The left column compares samples from
pancreatitis patients to samples from early-stage pancreatic cancer patients, and the right column compares pancreatitis to late-stage cancer. The
sensitivity and specificity at the threshold indicated by the dash line are given.
doi:10.1371/journal.pone.0029180.g002
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and a lack of elevation in both markers indicated a ‘‘control,’’ the
combined markers had better performance both sample sets 1 and
2. This improvement was consistent in the repeats of set 1, with the
same samples elevated only in one marker or the other (not
shown). The improved area-under-the-curve in receiver-operator-
characteristic analysis was not statistically significant (p.0.05) in
either set. However, the consistent observation of this improve-
ment for two different proteins, in two sample sets from different
institutions, and in repeat analyses supports the generality of the
finding.
We next asked whether MUC5AC and MUC16 could be used
together with total CA 19-9 to give additional improvement in
discriminating cases from controls. The three markers were
combined by defining a ‘‘case’’ as having an elevation in at least
one of the three markers and a ‘‘control’’ as being low in all three
markers. For such a combination rule, the thresholds for each
marker need to be individually set to give the best combined
performance. We scanned through the possible combinations of
thresholds for the three markers that would give a minimum
specificity of 98% (two false positives), which was chosen to reveal
cancer-specific patterns. A set of thresholds was achieved in which
most patients were elevated in total CA 19-9 and another, smaller
group was elevated in either CA 19-9-MUC5AC or CA 19-9-
MUC16 (Fig. 5). In sample set 1, 11 of the 40 patients that were
not elevated in total CA 19-9 were elevated in CA19-9-MUC5AC,
and eight were elevated in CA19-9-MUC16. A total of 15 patients
were detected by the panel that were not detected by the standard
CA 19-9 assay. In sample set 2, seven of the 51 patients low in total
CA 19-9 were elevated in either CA19-9-MUC5AC or CA19-9-
MUC16. At a specificity of 98%, sensitivity improved from 68% to
80% in sample set 1 and from 61 to 67% in sample set 2 (Table 2).
This approach also shows improvements at other specificities; if
the thresholds are set to a more permissive 75% specificity, a panel
detects seven of 15 patients that were low in total CA 19-9 in
sample set 1 (Fig. S3).
Standard CA 19-9 had a lower sensitivity for early-stage cancer
than late-stage cancer (Table 2), so we examined whether the
improvement using the panel held true for both early and late
stages. A direct comparison was achieved by adjusting the
threshold of standard CA 19-9 to give the same specificity (98%)
as the panel. Of the 14 patients detected by the panel in set 1 that
were not detected by CA 19-9 alone, just three were early stage,
and of the 14 additional patients detected by the panel in Set 2, six
were early stage (Table 2). Therefore, the panel has the potential
of improving the detection of early-stage cancer relative to the
standard CA 19-9 assay, but it is similar to standard CA 19-9 in
that it detects a higher percentage of late-stage cancer than early-
stage cancer.
While it was a relatively small subset of CA 19-9-low patients
that were picked up by the panel, the marker patterns were
Figure 3. Diversity in CA 19-9 levels on individual proteins. Raw antibody images are shown for patient samples representing diverse marker
patterns. Data from sample set 3 (replicate 1) are presented. A cancer sample (labeled ‘True positive’) and pancreatitis sample (labeled ‘False positive’)
that were high in total CA 19-9 (above a 75% specificity threshold) are in the top left, and pancreatitis samples that were low in total CA 19-9 (‘True
negatives’) are in the bottom left. Cancer samples that were low in total CA 19-9 are grouped by relatively high or low signal at one of the mucins in
the top right and bottom right, respectively. The sample identifier is given within each array. In the subgroup picked up by the panel (top-right), the
antibody showing elevation in a given sample is listed adjacent to each array. The corresponding antibody spots are underlined in white. Two arrays
for sample LC3607 are shown, one detected with BPL (rightmost column, row 2), and the other detected with CA19-9 (rightmost column, row 3). All
other arrays were detected with CA19-9. The bottom panels show maps of antibodies targeting MUC16 (left), MUC5AC (middle), and MUC1 (right).
doi:10.1371/journal.pone.0029180.g003
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consistent between the independent sample sets. In both sets 1 and
2, about a third of the patients detected by the panel were elevated
in only CA19-9-MUC5AC, another third elevated in only CA19-
9-MUC16, and another third elevated in both. The consistency
between the sample sets in the overall results supports that the
various patterns of marker expression, high in all or high in
individual members of the panel, represent biological subgroups
that may be observed in the larger population.
The use of three independent sets also gave information about
the relative merits of serum and plasma, since sample set 1 was
plasma and sets 2 and 3 were serum. The same markers were
found to be effective between sets 1, 2, and 3, with similar
relationships to total CA 19-9. That result suggests that the relative
levels between cases and controls are not greatly affected by the
mode of preparation of the sample. In addition, the reproducibility
of the measurements was similar between serum and plasma. Each
data set included repeated series of dilutions of pooled samples. At
a 10-fold dilution of the pool, representing concentrations similar
to the individual sample, the coefficient of variation between the
replicate measurements was 23% for the serum samples (from Set
2) and also 23% for the plasma samples (from Set 3) (data not
shown). That finding suggests that the stability of the markers is
not greatly affected by whether the samples are prepared as serum
or plasma.
Discussion
The need for improved blood markers for pancreatic cancer is
great. Such markers would have important applications in the
detection and diagnosis of the disease, leading to improved patient
management and outcomes. The sub-optimal performance of the
CA 19-9 assay may, in some cases, be due to the appearance of the
CA 19-9 carbohydrate antigen on carrier proteins that are not
specific to cancer. By detecting the antigen specifically on the
proteins that are the predominant carriers in cancer, improved
performance may result. We examined this possibility using
antibody arrays with glycan detection, which provided a
convenient approach to measuring the CA 19-9 antigen on
multiple, individual proteins. We found that the mucins MUC1,
MUC5AC, and MUC16 are indeed major cancer-associated
carriers of CA 19-9, but because of the diversity among patients in
the proteins that carry CA 19-9, the detection of CA 19-9 on any
single protein did not out-perform total CA 19-9. However, for
individual patients with low CA 19-9 in which a predominant
carrier was identified, selective discrimination from the pancrea-
titis controls was possible. A combination marker comprising total
CA 19-9 plus CA 19-9 on selected proteins could yield improved
sensitivity of cancer detection over total CA 19-9 alone. Similar
results were observed in two independent sample sets from two
different institutions. This work demonstrates the potential of
improving detection accuracy using glycan measurements on
individual proteins.
A new biomarker to more sensitively detect cancer relative to
benign disease conditions could be significant in a variety of ways.
A possible area of application would be to diagnose patients that
have pancreatic abnormalities as discovered by CT scan. Several
conditions in addition to malignancies produce abnormal
pancreatic findings by CT [16], such as cystic lesions, pancreatitis,
and common bile duct obstruction, and only some require further
intervention. Because no molecular marker exists to sort out the
conditions, nearly all patients go on to endoscopic ultrasound and
potential biopsy. A reduction in this invasive, costly, and risky
procedure is desirable, considering the high rate of patients with
benign conditions that receive it. The patients that might benefit
most from markers based on this strategy would be those with CA
19-9 levels that are below a threshold for disease-specific elevation
but above the analytical detection limit of the assay. For those
Figure 4. Correlations and complementarity between total CA
19-9 and CA 19-9 on MUC16 and MUC5AC. Each scatter plot
compares the values for total CA 19-9 (x axis) to the values for CA 19-9 on
MUC16 or MUC5AC. Each point is an individual sample. Samples from Set
1 are presented at top, and samples from Set 2 are presented in the
bottom panels. The dashed lines indicate representative thresholds for
each marker. The sensitivity and specificity given in each graph
represents the performance at those thresholds if a sample exceeding
either threshold is called a ‘‘case.’’ The red arrows indicate the samples
that are not elevated in total CA 19-9 but are elevated in CA 19-9 on an
individual protein. Each ROC curve shows the performance of CA 19-9
alone and the combination of CA 19-9 with the indicated marker. If a
sample was elevated in either marker, it was called a ‘‘case.’’ The asterisk
indicates the performance at the thresholds in the scatter plots.
doi:10.1371/journal.pone.0029180.g004
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patients, it may be possible to accurately determine who should be
referred for additional diagnostic workup.
Future work in the development of a biomarker includes further
validating and characterizing the improved sensitivity of the
current marker panel and determining the panel’s ability to meet
the performance needs of specific clinical applications. The most
effective validation will make use of samples that were collected in
the clinical setting and patient population intended for eventual
use, in this case patients with pancreatic abnormalities who are
being considered for referral for further diagnostic workup. In
addition, it will be important to develop clinical assays for these
markers. Clinical assays would ensure lack of interference from
potentially confounding factors and would provide the precision
and control over variability that are required to fully assess marker
performance.
Further biomarker discovery could be targeted to the subgroup
not detected by the panel (Fig. 5). For patients that may have weak
levels of the CA 19-9 antigen, yet the main protein carrier of the
Figure 5. Improved classification over CA 19-9 using a three-marker panel. Each column represents data from a patient sample and each
row represents a marker, with the bottom row indicating the patient classification. A threshold was set for each marker, and a yellow square indicates
the sample was above the threshold for that marker, and black indicates below the threshold. In the final row, a yellow square indicates the sample
was elevated in any of the three markers and classified as a ‘‘case.’’ The true positive (TP) cancer cases that were elevated in CA 19-9 are indicated by
‘TP, CA 19-9’, and the true positive cases elevated only in the other markers are indicated by ‘TP, Panel.’ The false negative (FN) cancer cases are
indicated by ‘FN,’ the false positive (FP) control cases that were elevated in a marker are indicated by ‘FP,’ and the true negative (TN) control cases
that were low in all markers are indicated by ‘TN.’ Data from Sample Set 1 is presented at top, and data from Sample Set 2 is below.
doi:10.1371/journal.pone.0029180.g005
Table 2. Comparison of the performance of total CA 19-9 and the marker panel in each set.
Set 1 Specificity Sensitivity Accuracy
All samples CA 19-9 alone 98% (103/105) 63% (79/125) 79%
Panel 98% (103/105) 74% (93/125) 85%
Early stage CA 19-9 alone 98% (103/105) 54% (29/54) 83%
Panel 98% (103/105) 59% (32/54) 85%
Late stage CA 19-9 alone 98% (103/105) 70% (50/71) 86%
Panel 98% (103/105) 86% (61/71) 93%
Set 2
All samples CA 19-9 alone 98% (86/88) 56% (74/132) 73%
Panel 98% (86/88) 67% (88/132) 79%
Early stage CA 19-9 alone 98% (86/88) 42% (25/60) 75%
Panel 98% (86/88) 52% (31/60) 79%
Late stage CA 19-9 alone 98% (86/88) 68% (49/72) 84%
Panel 98% (86/88) 79% (57/72) 89%
doi:10.1371/journal.pone.0029180.t002
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antigen is unknown, it would be valuable to identify the
predominant carrier of the antigen. New assays CA 19-9 on that
protein could provide selective detection of those patients, as
demonstrated here. For patients that have undetectable CA 19-9
levels, the detection of another glycan on the mucins or some other
protein carrier may provide discrimination. This situation was
present in patient 3607 (Fig. 3). This patient showed no CA 19-9
signal on any carrier but showed strong signal at the MUC5AC
capture antibody when detected by the lectin BPL. The glycan
bound by BPL, terminal beta-linked galactose, is distinct from the
glycan bound by CA 19-9, confirming the need for the detection of
additional glycans beyond CA 19-9. This result is consistent with
the fact that certain individuals, estimated to be around 5% of the
population, are genetically deficient in an enzyme that completes a
critical step in the biosynthesis of the CA 19-9 antigen [17,18].
Finally, for patients without detectable CA 19-9 or mucin, proteins
and glycans must be sought.
Improving the limit of detection of the analytical assay may also
enhance the ability to detect the cancer patients. Some of the
patients not detected in this study may have mucin proteins
secreted into the blood but at very low levels, which might be
detectable given a very sensitive assay. This point may be
especially important for early-stage cancer patients, which are
likely to have lower concentrations of tumor markers. Our data
show that we detect a subset of early-stage cancer patients (Table 2
and Fig. 5) but that late-stage patients are more frequently
elevated. Several options are available for improving the detection
limits of the assay. Amplification of the fluorescence signal is
possible using rolling-circle amplification [19,20] or tyramide
signal amplification [21]. A novel format that restricts the sample
to ultra-low detection volumes can lower detection limits using
enzyme-based chemiluminescence detection [22]. A new genera-
tion of electrochemical biosensors is achieving or surpassing
detection limits achieved by fluorescence [23], which provides
another possible route for the improved detection of cancer
patients.
The subgroups identified in this work may represent biologically
distinct subgroups of pancreatic cancer that have clinical
implications. Studies of cancers of other organs have identified
subcategories of disease defined by molecular characteristics [24],
but clear subcategories of pancreatic cancer have not emerged
despite the gene expression and molecular profiling studies that
have been performed on pancreatic ductal adenocarcinoma
[25,26], However, it is likely that defined subgroups of the disease
exist that have distinct molecular characteristics and that produce
distinct alterations in the blood. Future work will investigate
connections between distinct blood marker profiles and other
information about the tumor or patient. Given the roles of the
Lewis family of carbohydrate structures (of which the CA 19-9
antigen is a member) in modulating immunological and vascular
interactions [27,28], the possibility exists that differences in the
carrier protein of the CA 19-9 antigen would contribute to distinct
courses of tumor progression. For example, because sialyl LewisA
is a ligand for selectin receptors that initiate lymphocyte
interactions with vascular walls, high levels in the blood may
modulate inflammatory responses [27]. The modulation of mucin
function through altered glycosylation also might have biological
implications. The mucins have normal functions in the protection
and control of epithelial surfaces [11,29], and the increased
presence of Lewis antigens on mucins could have significant
physiological effects both in the local tumor environment and at
distant sites accessed through the lymph and circulation. Because
the CA 19-9 antigen is sialylated, mucins bearing that glycan
would not be cleared through the asialoglycoprotein receptors on
liver cells, allowing mucin levels to increase and remain high in the
circulation of cancer patients. Some evidence of direct immuno-
modulatory effects of tumor-derived mucins on leukocytes has
been uncovered [30,31,32].
The approach to biomarker development demonstrated here
may be useful in other biomarker applications. The detection of
glycans on specific proteins may yield greater accuracy for a
variety of disease states than by detecting just protein levels, as
with standard immunoassays, or just the levels of a particular
glycan on all proteins, as with the conventional CA 19-9 assay.
The antibody-lectin sandwich array provides an ideal format for
testing combinations of proteins and glycans for such investigations
[33]. The proteins and glycans to be targeted on the arrays can be
derived from known molecular alterations, such as mucins in
pancreatic cancer [11,29,34], or from genomics, proteomics, and
glycoproteomics studies. Glycoproteomics methods used in
combination with antibody arrays could represent a powerful
strategy for biomarker development [35], the former providing
potential new proteins and glycans to test, and the latter providing
an efficient and accurate means of testing multiple candidates.
Potential additional areas of application include screening for
colon cancer, which displays mucin and glycan alterations, and the
early detection of incipient cancer in chronic inflammatory
situations. It will be valuable to map the tissue-specificity of
protein carriers of cancer-associated glycans, which will increase
the information content of the assay.
In summary, an improvement over the conventional CA 19-9
assay may be achievable by detecting the CA 19-9 antigen on
specific proteins rather than on all protein carriers. The
identification of subgroups of patients based on CA 19-9 carrier
status suggests biologically distinct entities of the disease that will
be will be optimally detected by complementary markers. Using a
combination of total CA 19-9 and CA 19-9 on individual proteins,
the sensitivity of cancer detection was improved relative to CA 19-
9 alone in two independent sample sets from two different
institutions, achieving 67-80% sensitivity at 98% specificity. The
expansion of this panel with additional glycans and protein
carriers should further improve performance. Validation will be
performed using blinded samples collected from the setting of the
intended clinical application, in accordance with the developed
standards for biomarker validation [36].
Materials and Methods
Ethics statement
All sample collection and research was conducted under
protocols approved by the Institutional Review Boards at
Evanston Northwestern Healthcare, the University of Michigan
Medical School, the University of Pittsburgh School of Medicine,
and the Van Andel Research Institute. Written, informed consent
was obtained from all participants in the study.
Serum and plasma samples
Serum samples from Evanston Northwestern Healthcare and
the University of Michigan Medical School and plasma samples
(using EDTA as the anti-coagulant) from the University of
Pittsburgh School of Medicine were collected from pancreatic
cancer, pancreatitis and healthy subjects (Table 1). Early-stage
cancer was defined as stages I and II, and late-stage cancer was
defined as stages III and IV. The pancreatitis patients were a
mixture of chronic and acute. The control subjects were healthy
with no evidence of pancreatic, biliary or liver disease. The
samples at each site were collected using a standard operating
procedure based on the serum and plasma protocols from the
CA 19-9 on Specific Carrier Proteins
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Early Detection Research Network. All samples were stored at
280uC and sent frozen on dry ice. Each aliquot had been thawed
no more than three times before use.
Antibodies and lectins
The antibodies and lectins were obtained from various sources
(see Tables S1, S2, S3). All antibodies were screened for reactivity
and integrity using Western blots, purified, and prepared at
0.5 mg/ml in pH 7.2 phosphate-buffered saline (PBS) for non-
contact array printer and at 0.25 mg/ml in pH 7.2 PBS for
contact array printer. The steps of antibody purification included
ultracentrifugation at 47,000 g at 4 degrees for 1 hour and dialysis
(Slide-A-Lyzer Mini Dialysis Units, Pierce Biotechnology) against
pH 7.2 PBS at 4 degree for 2 hours.
Microarray fabrication
Approximately 170 pg (350 pl at 500 mg/ml or 700 pl at
250 mg/ml) of each antibody was spotted on the surfaces of ultra-
thin nitrocellulose-coated microscope slides (PATH slides, GenTel
Biosciences) by a non-contact microarrayer (sciFLEXARRAYER,
Scienion) performed at GenTel Biosciences (Madison, WI) for the
slides used in replicates 1 and 2 of sample set 1, and by a contact
microarrayer (2470, Aushon Biosciences) for the rest of the
experiments. Forty-eight identical arrays containing triplicates of
all antibodies were printed on each slide. Hydrophobic borders
were imprinted around each array using a stamping device
(SlideImprinter, The Gel Company, San Francisco, CA).
Microarray assays
Microarray sandwich assays were performed to measure
either the level of total CA19-9 or the glycan levels on the
proteins captured by the immobilized antibodies (Fig. 1a). The
sandwich assay consisted of four 1-hour-incubations in room
temperature (RT) with the following reagents: 1) blocking buffer
(PBS containing 0.5% Tween-20 (PBST0.5) and 1% BSA); 2) a
serum or plasma sample, diluted two-fold in 16TBS containing
0.08% Brij, 0.08 Tween-20, 50 mg/ml protease inhibitor
cocktail (Complete Protease Inhibitor Tablet, Roche Applied
Science), and a cocktail of IgG from mouse, goat, and sheep
each at 100 mg/ml and rabbit IgG at 200 mg/ml (Jackson
ImmunoResearch Laboratories, Inc.); 3) biotinylated detection
antibody or lectin (2 mg/ml), diluted in PBST0.1 containing
0.1% BSA; 4) streptavidin-phycoerythrin (10 mg/ml, Roche
Applied Science), diluted in PBST0.1 containing 0.1% BSA.
After each step, the slides were rinsed in three baths of PBST0.1
and dried by centrifugation (Eppendorf 5810R, rotor A-4-62,
15006 g).
The measurement of glycans by using lectins detection on the
captured proteins (Fig. 1a) was carried out as above, except the
glycans on the spotted antibodies were derivatized to prevent
lectin binding to the antibodies [12], and the arrays were probed
with glycan-binding lectins. Fluorescence emission from the
phycoerythrin was detected at 570 nm using a microarray
scanner (LS Reloaded, Tecan). All arrays within one slide were
scanned at a single laser power and detector gain setting. The
images were quantified using the software program GenePix Pro
5.0 (Molecular Devices, Sunnyvale, CA). Spots were identified
using automated spot-finding or manual adjustments for
occasional irregularities. The median local backgrounds were
subtracted from the median intensity of each spot, and triplicate
spots were averaged using the geometric mean. The coefficient of
variation between replicate analyzed spots was typically under
10%.
Statistical analyses and software
Pearson correlations, Student’s T-tests, and receiver-operator
characteristic analyses were calculated using Microsoft Excel. The
scatter and box plots were created using OriginPro 8, and figure
production was performed using Canvas X.
Supporting Information
Figure S1 Selection of antibodies that capture CA 19-9
carrier proteins. a) 12 serum samples (6 benign+6 cancer) were
incubated on arrays containing 58 different capture antibodies at
detected with the CA 19-9 antibody. A series of steps were taken to
select antibodies that capture CA 19-9 carrier proteins and that
have potential value in subsequent experiments. i) Antibodies were
removed that produced consistently low signal across all samples,
defined as an average fluorescence across all samples of ,1.5 time
the fluorescence in the PBS negative control array. ii) Next, we
removed antibodies that produced signals with a very low standard
deviation across samples, since a lack of change between samples
would not produce valuable information in later experiments. The
threshold was ,400 RFU. iii) Finally, we compared signals
between the pancreatic cancer sera and the control pancreatitis
sera to identify antibodies potentially showing differences between
the groups using the Mann-Whitney test. Since this was a
preliminary analysis the significance threshold was set at a=0.10
b) The process was repeated for 16 of the most promising
antibodies from the first run, using a set of 44 serum samples (4
healthy+20 benign+20 cancer). The more powerful student’s t-test
was used due to the larger sample size, but with a more stringent
a=0.05. c) Fluorescence values across the case and control
samples for two of the best capture antibodies, anti-MUC5AC and
anti-MUC16.
(TIF)
Figure S2 CA 19-9 immunoblots of selected samples. Of
fundamental interest is the distribution of CA 19-9 carrier
proteins in these subgroups. An approach to visualize the range of
proteins carrying the CA 19-9 antigen is to fractionate the plasma
proteins using SDS-PAGE and immunoblot for the CA 19-9
antigen, which we did for representative samples from the
subgroups defined by CA 19-9 carrier protein status. The
indicated plasma samples from Set #1 were fractionated on a
4–12% gradient polyacrylamide gel and probed by Western blot
using the CA 19-9 antibody. The samples that were high in CA
19-9 by microarray showed a broad range of molecular weights
with high signal, indicating many proteins containing the CA 19-
9 antigen. The samples that were below the 75% specificity
threshold but that showed significant signal at the mucin proteins
showed only faint bands at high molecular weights (.150 kD);
and the samples not detected by any marker showed no
discernable or only faint bands. This results shows that no major
protein carriers of the CA 19-9 antigen, at least in the molecular
weights observed in this format, are present in the low CA 19-9
samples. Thus, the identification of cancer in the remaining
samples not picked up by the panel most likely will rely on
additional proteins or glycans.
(TIF)
Figure S3 Increased sensitivity using markers comple-
mentary to total CA 19-9. Data from sample set 1, replicate 1
are presented. a) Comparison of CA19-9 on MUC16 to total
CA19-9. The levels of CA 19-9 on MUC16 for each sample are
plotted along the vertical axis, and the total CA 19-9 levels for the
same samples are plotted along the horizontal axis. The plot shows
only the lower 50% of the samples by total CA 19-9. The vertical
CA 19-9 on Specific Carrier Proteins
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line indicates the threshold defined to give 75% specificity by total
CA19-9. The horizontal dashed line indicates a threshold for
CA19-9 on MUC16 which would result in the detection of
additional cancer samples (noted by the arrows) without detecting
additional pancreatitis samples. b) Combined results of total
CA19-9 and four additional complementary markers. The samples
are ordered in the columns (Bn is benign, EarlyC is early-stage
cancer, LateC is late-stage cancer, Cancer is unknown stage
cancer) and the markers in the rows. The threshold for total
CA19-9 was set to 75% specificity, and the threshold for each
additional marker was defined as in panel a. A yellow square
indicates a measurement above the threshold, a black square
indicates below the threshold, and gray squares are missing data.
The blue box denotes the cancer samples not detected by CA 19-9
(CA 19-9 measurements in the red box). The samples picked up by
the additional markers are highlighted by blue column labels.
(TIF)
Table S1 Antibodies used in the large-scale screening
for CA 19-9 carrier proteins.
(DOCX)
Table S2 Antibodies used for the follow up experiments
in screening for CA 19-9 carrier proteins.
(DOCX)
Table S3 Antibodies used on the arrays and for
detection in the biomarker profiling experiments.
(DOCX)
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